Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) CEO David Portnoy bought 20,000 shares of the company's stock in a transaction that occurred on Tuesday, November 8th. The stock was purchased at an average cost of $4.89 per share, for a total transaction of $97,800.00. Following the transaction, the chief executive officer now owns 204,080 shares in the company, valued at approximately $997,951.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Portnoy also recently made the following trade(s):

• On Thursday, November 10th, David Portnoy acquired 3,850 shares of Cryo-Cell International stock. The stock was acquired at an average price of $4.90 per share, for a total transaction of $18,865.00.

Cryo-Cell International Stock Up 3.8 %

CCEL stock opened at $4.95 on Friday. Cryo-Cell International, Inc. has a twelve month low of $4.68 and a twelve month high of $14.00. The company has a market cap of $42.17 million, a price-to-earnings ratio of 33.00 and a beta of 0.35. The business has a 50 day moving average price of $5.83 and a two-hundred day moving average price of $5.96.

Cryo-Cell International Dividend Announcement

The firm also recently declared a dividend, which was paid on Friday, September 9th. Shareholders of record on Friday, September 2nd were issued a dividend of $0.90 per share. The ex-dividend date of this dividend was Thursday, September 1st.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV grew its position in shares of Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,135 shares of the company's stock after buying an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned approximately 1.47% of Cryo-Cell International worth $732,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.01% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Maxim Group initiated coverage on shares of Cryo-Cell International in a research report on Monday, August 29th. They issued a "buy" rating and a $12.00 target price for the company.

Cryo-Cell International Company Profile

(Get Rating)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

Featured Stories

• Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
• Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
• Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
• Six Flags is a Ride You Don't Want to Get Stuck On
• Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
• Hanesbrands May be Signaling a Bad Week for Retail Stocks

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.